ERA Biotech

About ERA Biotech

ERA Biotech, founded in 2002 and headquartered in Barcelona, Spain, operates within the biotechnology sector, specializing in protein-based technologies. The company has developed two proprietary platforms, Zera® and Splittera®, which form the core of its business. These technologies are applied to enhance existing enzymes, develop novel recombinant and plasmid DNA vaccines, and create advanced protein cleavage and purification systems.

The company's business model appears to be centered on a combination of in-house product development and technology licensing. It leverages its platforms to create innovations that can be marketed or out-licensed to partners in the pharmaceutical and biotech industries. This strategy allows the firm to address multiple market segments, including human and animal health, by providing tools for vaccine development and protein manufacturing. The Zera® technology, for instance, functions as a fusion tag that simplifies the purification of recombinant proteins and promotes the formation of stable, artificial protein bodies. The Splittera® system offers a highly specific and controllable protein cleavage mechanism, valuable in bioprocessing and diagnostics.

Financially, ERA Biotech has navigated several funding stages, starting with a seed round in November 2002 and progressing through early-stage venture capital in 2006 and a Series A round in 2008, raising a total of $14.9M. Key investors have included AXIS Participaciones Empresariales, Highgrowth Partners, and Uninvest. While the company was noted as 'Generating Revenue' in 2008, a more recent profile indicates a status of 'Bankruptcy: Liquidation', suggesting a significant shift in its operational standing.